Enrolling: Myelofibrosis patients who are not candidates or don't qualify for Ruxolitinib
Drug: Sl-401
Company: Stemline Therapeutics
Study name: SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)
|